Literature DB >> 17296665

Hydroxychloroquine-induced toxic myopathy causing respiratory failure.

Anita K Siddiqui1, Seymour I Huberfeld, Karen M Weidenheim, Kenneth R Einberg, Linda S Efferen.   

Abstract

Chloroquine and hydroxychloroquine (HCQ) are commonly prescribed antimalarial agents used for a variety of systemic diseases. HCQ neuromyotoxicity is a rare complication characterized by proximal muscle weakness, normal creatinine kinase levels, and characteristic ultrastructural changes on muscle biopsy of curvilinear body formation. In this report, we describe a patient with rheumatoid arthritis and respiratory failure associated with proximal myopathy secondary to HCQ. Characteristic changes on muscle biopsy were present. Patients treated with HCQ in whom proximal myopathy, neuropathy, or cardiomyopathy develop should be evaluated for possible HCQ toxicity. Clinicians should be aware of this unusual complication of antimalarials, as discontinuation of the agent may result in clinical improvement.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17296665     DOI: 10.1378/chest.06-1146

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  15 in total

1.  Hydroxychloroquine on the Pulmonary Vascular Diseases in Interstitial Lung Disease: Immunologic Effects, and Virus Interplay.

Authors:  Jun-Jun Yeh; Shih-Hueh Syue; Yi-Fun Sun; Yi-Ting Yeh; Ya-Chi Zheng; Cheng-Li Lin; Chung Y Hsu; Chia-Hung Kao
Journal:  Biomedicines       Date:  2022-05-31

Review 2.  Side Effects of Chloroquine and Hydroxychloroquine on Skeletal Muscle: a Narrative Review.

Authors:  Alzira Alves de Siqueira Carvalho
Journal:  Curr Pharmacol Rep       Date:  2020-10-31

3.  Curvilinear bodies are associated with adverse effects on muscle function but not with hydroxychloroquine dosing.

Authors:  Thomas Khoo; Sophia Otto; Caroline Smith; Barbara Koszyca; Sue Lester; Peter Blumbergs; Vidya Limaye
Journal:  Clin Rheumatol       Date:  2016-09-14       Impact factor: 2.980

Review 4.  Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review.

Authors:  Eleni Korompoki; Maria Gavriatopoulou; Rachel S Hicklen; Ioannis Ntanasis-Stathopoulos; Efstathios Kastritis; Despina Fotiou; Kimon Stamatelopoulos; Evangelos Terpos; Anastasia Kotanidou; Carin A Hagberg; Meletios A Dimopoulos; Dimitrios P Kontoyiannis
Journal:  J Infect       Date:  2021-05-14       Impact factor: 6.072

Review 5.  Antimalarial myopathy in a systemic lupus erythematosus patient with quadriparesis and seizures: a case-based review.

Authors:  Kashif Jafri; Hengameh Zahed; Katherine D Wysham; Sarah Patterson; Amber L Nolan; Matthew D Bucknor; R Krishna Chaganti
Journal:  Clin Rheumatol       Date:  2017-02-24       Impact factor: 3.650

6.  Clinical utility of LC3 and p62 immunohistochemistry in diagnosis of drug-induced autophagic vacuolar myopathies: a case-control study.

Authors:  Han S Lee; Brianne H Daniels; Eduardo Salas; Andrew W Bollen; Jayanta Debnath; Marta Margeta
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

Review 7.  Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review.

Authors:  Anwar M Hashem; Badrah S Alghamdi; Abdullah A Algaissi; Fahad S Alshehri; Abdullah Bukhari; Mohamed A Alfaleh; Ziad A Memish
Journal:  Travel Med Infect Dis       Date:  2020-05-06       Impact factor: 6.211

Review 8.  Hydroxychloroquine: from malaria to autoimmunity.

Authors:  Ilan Ben-Zvi; Shaye Kivity; Pnina Langevitz; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

9.  Chloroquine and Hydroxychloroquine Myopathy: Clinical Spectrum and Treatment Outcomes.

Authors:  Elie Naddaf; Pritikanta Paul; Omar F AbouEzzeddine
Journal:  Front Neurol       Date:  2021-02-02       Impact factor: 4.003

10.  Minocycline-associated rimmed vacuolar myopathy in a patient with rheumatoid arthritis.

Authors:  Kota Bokuda; Keizo Sugaya; Shunichiro Tamura; Kazuhito Miyamoto; Shiro Matsubara; Takashi Komori
Journal:  BMC Neurol       Date:  2012-11-21       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.